secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001193125-24-193913
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics Q2 net loss $17.9M; CMO departs; SPR720 data expected 4Q 2024
--------------------------------------------------------------------------------

- Net loss $17.9M ($0.33/share) vs $11.9M loss ($0.23) in Q2 2023; revenue $10.2M up from $2.7M.
- Cash $63.5M as of June 30, 2024; runway into late 2025 reaffirmed.
- SPR720 Phase 2a NTM-PD trial enrollment completed; preliminary data expected 4Q 2024.
- CMO Kamal Hamed departing Aug 29; Board member John Pottage appointed Special Advisor to oversee medical function.
- Tebipenem HBr Phase 3 PIVOT-PO enrollment on track; target ~2,648 patients, completion H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524193913/0001193125-24-193913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312524193913/d871341d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-193913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer